PerkinElmer has appointed Daniel Marshak as vice president and chief scientific officer. Marshak will be responsible for PerkinElmer's R&D strategy, and for "helping drive its growth strategies in the emerging areas of personalized medicine and predictive diagnostics," the company said in a statement.
Marshak joins the firm from Cambrex, where he was vice president and CTO. He currently serves as an adjunct associate professor at Johns Hopkins University School of Medicine and is also an advisor to PharmaFrontiers.
Marshak holds a PhD from Rockefeller University and a BA in biochemistry and molecular biology from Harvard University.
Invitrogen this week announced the availability of advanced vectors for its Vivid Colors fluorescent proteins. Invitrogen said that Vivid Colors proteins, derived from the Aequorea victoris jellyfish, improve upon Enhanced Green Fluorescent Protein because they are not prone to aggregation, are enhanced for extreme fluorescence, and are optimized for mammalian expression. In addition, the Vivid Colors proteins can fluoresce for up to 24 hours and in multiple colors for multiplexed visualization.
Li-Cor has introduced new IRDye Western kits for the Odyssey Infrared Imaging System. The kits include IRDye 800 CW and IRDye 680 labeled secondary antibodies, Odyssey Blocking Buffer, and PVDF membranes. Li-Cor's IRDye reagents can be used for protein analysis including Westerns, In-cell Western assays, in vivo imaging, whole-tumor imaging, and in situ analysis and characterization of tumor sections.